hormone-therapy
发表于 2025-3-21 19:41:57
书目名称Cancer Immunotherapy Meets Oncology影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0221139<br><br> <br><br>书目名称Cancer Immunotherapy Meets Oncology影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0221139<br><br> <br><br>书目名称Cancer Immunotherapy Meets Oncology网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0221139<br><br> <br><br>书目名称Cancer Immunotherapy Meets Oncology网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0221139<br><br> <br><br>书目名称Cancer Immunotherapy Meets Oncology被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0221139<br><br> <br><br>书目名称Cancer Immunotherapy Meets Oncology被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0221139<br><br> <br><br>书目名称Cancer Immunotherapy Meets Oncology年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0221139<br><br> <br><br>书目名称Cancer Immunotherapy Meets Oncology年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0221139<br><br> <br><br>书目名称Cancer Immunotherapy Meets Oncology读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0221139<br><br> <br><br>书目名称Cancer Immunotherapy Meets Oncology读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0221139<br><br> <br><br>
高歌
发表于 2025-3-22 00:18:44
http://reply.papertrans.cn/23/2212/221139/221139_2.png
PURG
发表于 2025-3-22 03:18:22
http://reply.papertrans.cn/23/2212/221139/221139_3.png
加入
发表于 2025-3-22 07:21:42
http://reply.papertrans.cn/23/2212/221139/221139_4.png
MAPLE
发表于 2025-3-22 11:16:08
http://reply.papertrans.cn/23/2212/221139/221139_5.png
Dignant
发表于 2025-3-22 15:25:28
Evolution of the Regulatory Landscape for Immunomodulatory Compounds and Personalized Therapeutic Ca safety profile on the other. Here, we briefly summarize the regulatory classification of immunotherapy approaches. The second part focuses on the evolving regulatory landscape for nonpersonalized and personalized cancer vaccines that have been in the focus of the CIMT regulatory research group during the last years.
Dignant
发表于 2025-3-22 17:13:20
http://reply.papertrans.cn/23/2212/221139/221139_7.png
表被动
发表于 2025-3-22 21:35:17
The Express Drivers: Chimeric Antigen Receptor-Redirected T Cells Make It to the Clinic) conditions, engineered by viral vector- or nucleic acid-based gene transfer with the CAR, amplified to therapeutic numbers, and readministered to the patient. Successes in recent trials sustain the hope that specifically redirected patient T cells can control cancer in the long term.
亵渎
发表于 2025-3-23 03:37:23
Book 2014er Immunotherapy Meets Oncology. is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients..
HARD
发表于 2025-3-23 06:16:42
Book 2014nto an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identificat